News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
Manufacturer's illustration of how Keytruda stops cancer cells hiding from the immune system.

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer

Aduro Biotech, Inc. and Merck are launching a Phase 1 study of the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Merck’s anti-PD-1 therapy KEYTRUDA (embolismic) for the treatment of gastric cancer. “The combination of inducing an immune response through CRS-207, while simultaneously suppressing the cancer’s ability to evade the immune system through a PD-1 checkpoint inhibitor, has resulted in synergistic anti-tumor activity in pre-clinical studies.”

Read Source
X